Pharmalot... Pharmalittle... Good Morning

Good morning, everyone, and how are you today? Was the weekend relaxing? We hope so. Now, though, the time has come to resume that routine of meetings and deadlines. It never ends, does it? So to cope, yes, are we brewing our mandatory cup of stimulation and invite you to join us. Or grab a bottle of water, if you prefer. This promises to be a busy week so there is no need to tally. Here are some tidbits to get you going. Hope your day goes well and stay in touch...

FDA Skeptical Of Amgen Drug Ahead Of Panel Meeting (The Street)

Orexigen And FDA Agree On Trial Design For Diet Drug (Reuters)

Supermarket Chains Object To Express Scripts-Medco Deal (Reuters)

FDA Wants More Power To Adopt Nationwide ePedigree (InPharma Technologist)

Sanofi Faces Uphill Battle In Multiple Sclerosis Market (Reuters)

Novartis Resumes Shipping Animal Meds Made In Nebraska (Veterinary Practice News)

Glaxo To Reveal Results Of Research Funding Competition (The Telegraph)

Five Years After HPV Vaccine Mandate, Virginia Remains Split (Virginian Pilot)

Allegan To Rely Less On US For Sales (Reuters)

Whistleblower Program Yields Payoffs In Korea (Korea Times)

Venezuela Will Nationalize Companies Over Price Controls (Bloomberg News)

Medicaid Rule Change Could Slash State Rx Bills (Boston Herald)

NY Seniors Struggle After Changes To Rx Program (Ithaca Journal)

DEA Suspends Cardinal Health Facility (Lakeland Ledger)

Poland Halts Ratification Of ACTA (Washington Post)

EDITOR’S NOTE: Please check this post for updates throughout the morning

Coffee pix thx to chichcacha flickr creative commons